Company / Return on Equity (ROE)
Marker Therapeutics, Inc. Return on Equity (ROE) History
FY2018-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-95.2%
FY2021
5-year range
-300.2% / -48.6%
FY2018-FY2021
Trend
-95.9%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Marker Therapeutics, Inc. reports negative total equity of -95.2% in FY2021. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-95.2% in FY2021.
Improved from -300.2% to -95.2% over the past 3 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +205.0pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2021, return on equity (roe) decreased 95.9% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2021 | -95.2% | -95.9% |
| FY2019 | -48.6% | +83.8% |
| FY2018 | -300.2% | - |
As of FY2021 · SEC 10-K · Updated Jun 28, 2026